美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

三生製藥

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

資料載入中...

總覽公司新聞公告

《大行報告》富瑞下調三生製藥(01530.HK)目標價至9元評級“持有”

阿斯达克财经

《半日速報》恒指升210點; 恒生科技指數升47點美團升逾3% 百威亞太、九毛九、中國中免、六福、三生製藥創新高

阿斯达克财经

三生製藥(01530)委任張丹為獨立非執行董事

【港股通】三生製藥(01530)漲逾4% 大摩料其今年銷售增長目標升至雙位數

凤凰网港股

港股異動 | 三生製藥(01530)續漲5%、本月累升40% 大摩上調銷售預測及目標價特比澳新增上市申請

*大摩上調三生製藥(01530.HK)目標價至7.5元評級「與大市同步」

港股異動 | 三生製藥(01530)升8% 特比澳兒童ITP適應症申報上市國信維持“買入”

港股異動 | 三生製藥(01530)升6% 特比澳新增兒童ITP適應症上市申請獲受理

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SSRX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSRX\",,,,,undefined,":{"symbol":"SSRX","market":"US","secType":"STK","nameCN":"三生製藥","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"07-18 14:31:47 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1752868800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SSRX\",,,,,undefined,":{"symbol":"SSRX","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SSRX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2304574955","title":"《大行報告》富瑞下調三生製藥(01530.HK)目標價至9元  評級“持有”","url":"https://stock-news.laohu8.com/highlight/detail?id=2304574955","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2304574955?lang=zh_tw&edition=fundamental","pubTime":"2023-01-18 09:54","pubTimestamp":1674006840,"startTime":"0","endTime":"0","summary":"富瑞发表研究报告指，三生制药的核心产品特比澳获中国工信部审核，用于治疗在儿童或青少年的慢性原发性免疫性血小板减少症，数据显示产品三期临床研究已达到预设有效率主要终点，见效快并具良好安全性。考虑到公司的产品管线、市场竞争、合作、监管等因素，富瑞将三生制药目标价由10元降至9元，评级“持有”。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20191009132908649_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1239807/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["01530","SSRX"],"gpt_icon":0},{"id":"2301728928","title":"《半日速報》恒指升210點; 恒生科技指數升47點 美團升逾3% 百威亞太、九毛九、中國中免、六福、三生製藥創新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2301728928","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2301728928?lang=zh_tw&edition=fundamental","pubTime":"2023-01-05 12:12","pubTimestamp":1672891920,"startTime":"0","endTime":"0","summary":"恒指半日收21,003点，升210点或1.0%。恒生科技指数报4,474点，升47点或1.1%。国指升84点或1.2%，报7,150点。沽空资料截至 2023-01-04 16:25。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190213170708072_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190213170708072_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1236800/latest-news/HK6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1720050803.USD","LU0051755006.USD","LU0456846285.SGD","BK1233","513600","LU0320764599.SGD","BK1224","LU1328615791.USD","LU0348825331.USD","LU1807302812.USD","SSRX","LU0577902371.SGD","LU0052750758.USD","LU1794554557.SGD","HSI","LU0417516738.SGD","LU0359201612.USD","09922","LU0348735423.USD","BK1589","LU1242518931.SGD","LU1023057109.AUD","LU0128522157.USD","BK1593","LU0417516902.SGD","LU0456827905.SGD","BK1591","90013","QNETCN","LU0878005551.USD","LU0348814723.USD","01530","LU0431992006.USD","LU1688375341.USD","LU0543330483.HKD","LU0348805143.USD","MCHmain","LU0072913022.USD","LU0873338254.USD","LU0918141887.USD","LU0823040885.USD","LU0708995583.HKD","LU0577902298.EUR","BK1142","LU0320764755.SGD","BK1521","01880","LU0577902538.SGD","LU0326950275.SGD","HHImain"],"gpt_icon":0},{"id":"2295908023","title":"三生製藥(01530)委任張丹為獨立非執行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2295908023","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2295908023?lang=zh_tw&edition=fundamental","pubTime":"2022-12-30 20:12","pubTimestamp":1672402326,"startTime":"0","endTime":"0","summary":"智通财经APP讯，三生制药(01530)发布公告，唐柯先生辞任公司非执行董事及薪酬委员会成员，自2022年12月30日起生效。此外，张丹博士已获委任为公司独立非执行董事及薪酬委员会成员，自2022年12月30日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/855494.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1593","BK1161","BK1583","SSRX"],"gpt_icon":0},{"id":"2285883323","title":"【港股通】三生製藥(01530)漲逾4% 大摩料其今年銷售增長目標升至雙位數","url":"https://stock-news.laohu8.com/highlight/detail?id=2285883323","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2285883323?lang=zh_tw&edition=fundamental","pubTime":"2022-11-22 14:58","pubTimestamp":1669100296,"startTime":"0","endTime":"0","summary":"三生制药(01530)盘中走强，午后维持高位，最新报7.7港元，涨4.05%，成交额1.58亿港元。大摩发研报指，由于在疫情下内地药品集中采购实施日期进一步推迟等，预期三生制药今年的销售增长目标会由10%以下，调升至双位数；至于盈利因汇兑收益影响，估计会增长20%至30%。该行将三生制药目标价由6.2港元升21%至7.5港元，评级维持“与大市同步”，并调升集团今年至2024年销售预测分别5%、6%及7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=a4c4deed12bd620629bc4945d5f50524","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989772923.USD","LU1074936037.SGD","LU0971096721.USD","BK4585","BK4127","BK4504","BK4581","LU1363072403.SGD","LU1989772840.SGD","BK4534","01530","MS","BK1161","BK1593","LU1668664300.SGD","LU0106831901.USD","BK1583","SSRX"],"gpt_icon":0},{"id":"2285500763","title":"港股異動 | 三生製藥(01530)續漲5%、本月累升40% 大摩上調銷售預測及目標價 特比澳新增上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2285500763","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2285500763?lang=zh_tw&edition=fundamental","pubTime":"2022-11-22 11:39","pubTimestamp":1669088366,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药持续活跃，早盘最高触及7.85港元，月内，股价累升约40%。大摩最新表示，预计公司将上调销售增长目标。近日，核心产品特比澳新上市申请获受理，用于治疗儿童ITP。截至发稿，三生制药涨4.19%，报7.71港元，成交额1.03亿港元。日前，摩根士丹利发布更新报告称，预计三生制药今年的销售增长目标调升至双位数，盈利预测增长20%至30%。大摩上调公司目标价，由6.2港元升至7.5港元，并调升公司22年-24年销售预测分别5%、6%及7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/835202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SSRX","01530"],"gpt_icon":0},{"id":"2285006259","title":"*大摩上調三生製藥(01530.HK)目標價至7.5元  評級「與大市同步」","url":"https://stock-news.laohu8.com/highlight/detail?id=2285006259","media":"AAFN","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2285006259?lang=zh_tw&edition=fundamental","pubTime":"2022-11-22 10:15","pubTimestamp":1669083319,"startTime":"0","endTime":"0","summary":"~阿思达克财经新闻网址: www.aastocks.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1228058&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks","symbols":["01530","SSRX"],"gpt_icon":0},{"id":"2285333015","title":"港股異動 | 三生製藥(01530)升8% 特比澳兒童ITP適應症申報上市 國信維持“買入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2285333015","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2285333015?lang=zh_tw&edition=fundamental","pubTime":"2022-11-21 11:22","pubTimestamp":1669000954,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药再度显著走强，早盘升约8%。近日，公司核心产品特比澳新上市申请获NMPA受理，用于治疗儿童或青少年ITP。截至发稿，三生制药涨8.29%，报7.45港元，成交额0.93亿港元。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比约51%。公司盈利能力强，现金流充沛，维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/834356.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","BK1593","ITP","BK1161","BK4199","BK1583","SSRX"],"gpt_icon":0},{"id":"2282575061","title":"港股異動 | 三生製藥(01530)升6% 特比澳新增兒童ITP適應症上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2282575061","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2282575061?lang=zh_tw&edition=fundamental","pubTime":"2022-11-10 14:28","pubTimestamp":1668061688,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，三生制药再度活跃，午后升约6%。截至发稿，三生制药涨5.65%，报6.73港元，成交额1.52亿港元。11月9日，三生制药宣布，公司向NMPA提交的重组人血小板生成素注射液（特比澳）新上市申请已于日前获得受理，用于治疗儿童或青少年的持续性或慢性原发免疫性血小板减少症。特比澳作为三生制药自主研发的全球唯一商业化的重组人血小板生成素产品，2005年产品成功上市。今年上半年，特比澳实现销售15.75亿元，在公司收入中占比达50.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/827905.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01530","SSRX","BK1593","BK4199","BK1161","ITP","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SSRX\",market:\"US\",delay:false,,,undefined,":{}}}